TICKERNERD
Menu
QTTBQTTBHealthcare · Biotechnology

QTTB Stock Forecast: Q32 Bio, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$8.09
+1.25% on the day

The 6 Wall Street analysts covering Q32 Bio, Inc. hold a median 12-month price target of $36 — +345.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 8 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$237.9M
Ticker Nerd rank
83 / 100
Median analyst target
$36
Analysts covering
6
Revenue$0.0
Operating income−$9.1M
Net income−$8.9M
Free cash flow−$3.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.9%
1M
−30.8%
YTD
+143.7%
1Y
+170.6%
From 52W high
−62.2%
From 52W low
+319.2%
$2
$21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

QTTB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Q32 Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
83 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
90
Quality
89
Value
79
Size
65
Growth
65
Revisions
62
Issuance
58
Volatility
48
Accruals
17

Momentum (90): The shares have been drifting up relative to others.

Accruals (17): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

QTTB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on QTTB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26QTTBHigh $59Median $36Low $29

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $29Median $36High $59

The green dot is the last close — the median target sits +345.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
28 Sept 2026JefferiesInitiatesBuy$29
24 Aug 2026Morgan StanleyInitiatesOverweight$34
24 Aug 2026Morgan StanleyInitiatesOverweight—
28 July 2026HC Wainwright & Co.MaintainsBuy—
28 July 2026HC Wainwright & Co.MaintainsBuy$13 → $36
13 July 2026OppenheimerMaintainsOutperform$20 → $40
13 July 2026OppenheimerMaintainsOutperform—
13 July 2026Wells FargoUpgradeOverweight$66
13 July 2026Wells FargoUpgradeOverweight—
22 May 2026MizuhoInitiatesOutperform$14
22 May 2026MizuhoInitiatesOutperform—
18 May 2026Cantor FitzgeraldInitiatesOverweight—
5 May 2026HC Wainwright & Co.ReiteratesBuy—
25 Feb 2026HC Wainwright & Co.InitiatesBuy—
12 Mar 2025Wells FargoMaintainsEqual-Weight—
11 Feb 2025BMO CapitalDowngradeMarket Perform—
11 Feb 2025Piper SandlerDowngradeNeutral—
12 Dec 2024BMO CapitalMaintainsOutperform—
12 Dec 2024GuggenheimDowngradeNeutral—
11 Dec 2024Leerink PartnersDowngradeMarket Perform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. QTTB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

QTTB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Q32 Bio, Inc. returned +170.6% against +16.2% for the S&P 500, dividends included.

QTTB vs S&P 500, last 12 monthsTotal return, rebased to 100
0100200300400500600700Jan 26Apr 26Jul 26Oct 26QTTBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

QTTB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
1
Fundamentals

Q32 Bio, Inc. (QTTB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.5×

Cheaper than 69% of US stocks

Price / sales
4.4×

Cheaper than 27% of US stocks

Price / book
1.8×

Cheaper than 48% of US stocks

EV / EBITDA
6.4×

Cheaper than 50% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
39.9%

Higher than 92% of US stocks

Net margin
62.9%

Higher than 97% of US stocks

Returns & dividend
Return on equity
72.1%

Higher than 95% of US stocks

Return on assets
14.7%

Higher than 97% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Q32 Bio, Inc. (QTTB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Q32 Bio, Inc. has a market value of $237.9M and an enterprise value of $140.5M.

  • Revenue in the twelve months to 30 June 2026: $53.7M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: $33.8M, a 62.9% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$19.8M.

  • Shares outstanding: 29.8M.

  • Trailing P/E: 2.5×; forward P/E: −7.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Q32 Bio, Inc. employs 22 people — $2.4M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

QTTB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
QTTBQ32 Bio, Inc.$237.9M
83
IMRXImmuneering Corp.$241.5M
39
PYXSPyxis Oncology, Inc.$237.7M
73
ZNTLZentalis Pharmaceuticals, Inc.$237.6M
59
FATEFate Therapeutics, Inc.$247.6M
96
UPBUpstream Bio, Inc.$249.2M
26
CAMPCAMP4 Therapeutics Corp.$232.2M
61

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Q32 Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest QTTB news & analysis

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

PRNewsWire · 30 Sept 2026positive

Q32 Bio presented late-breaking results from Part B of the SIGNAL-AA Phase 2a trial of bempikibart in alopecia areata at the European Academy of Dermatology and Venereology Congress 2026, including data from the 36-week treatment period and a 16-week off-drug period. The company reported clinically meaningful efficacy on primary and key secondary endpoints, durable responses, biomarker and biopsy findings consistent with its mechanism of action, and a generally well-tolerated safety profile with no new safety signals.

Why it matters — The positive efficacy and durability data support Q32 Bio's plan to advance bempikibart into a registration-directed program for alopecia areata beginning in the first half of 2027.

Q32 Bio: Durable Hair Regrowth Remains The Goal

Seeking Alpha · 26 Sept 2026neutral

Seeking Alpha discusses Q32 Bio's bempikibart as a potential treatment for durable hair regrowth in alopecia areata, noting that its advantage still depends on broader clinical validation. The article highlights the company's improved short-term financing as de-risking, with upcoming updates in 2H2026, 1H2027, and 2H2027 seen as key to the bull case.

Why it matters — QTTB watchers would care because the piece frames bempikibart's clinical validation and the company's near-term financial runway as central to the stock's outlook over the next few years.

Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026

PRNewsWire · 21 Sept 2026neutral

Q32 Bio announced that additional 36-week results and initial findings from the 16-week off-drug period of Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart in alopecia areata will be presented as late-breaking oral and poster presentations at the EADV Congress in Vienna, September 30 – October 3, 2026.

Why it matters — QTTB watchers would care because the presentation will provide new clinical data on bempikibart's longer-term efficacy and durability in severe or very severe alopecia areata patients.

Q32 Bio Inc. (QTTB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 15 Sept 2026neutral

Q32 Bio, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, where the company's remarks were captured in a transcript published by Seeking Alpha.

Why it matters — The presentation gives investors and watchers of QTTB insight into the company's latest corporate updates and its engagement with the investment community at a major healthcare conference.

Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D.

PRNewsWire · 14 Sept 2026positive

Q32 Bio announced the appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., to its leadership team. Both bring extensive late-stage clinical development and regulatory experience in dermatology and drug development.

Why it matters — For QTTB watchers, these appointments add senior executives with deep late-stage clinical and regulatory expertise as the company advances its therapies for alopecia areata and other autoimmune and inflammatory diseases.

FAQ

Frequently asked questions about QTTB stock

What is the QTTB stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Q32 Bio, Inc. have a median 12-month price target of $36, with estimates ranging from $29 to $59. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is QTTB stock a buy right now?

Of the 6 analysts covering Q32 Bio, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Q32 Bio, Inc. 83 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank QTTB?

As at 8 Oct 2026, Q32 Bio, Inc. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (90 of 100).

Will QTTB stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +345.0% from the last close, and Ticker Nerd's factor model ranks Q32 Bio, Inc. 83 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the QTTB stock forecast for 2030?

No analyst covering Q32 Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QTTB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $29 to $59 over the next 12 months.

How has QTTB stock performed over the past year?

Q32 Bio, Inc. returned +170.6% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Q32 Bio, Inc. do?

Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing biologic therapies for autoimmune and inflammatory diseases driven by immune system dysfunction.

What is the latest news on QTTB?

The most recent item we track (PRNewsWire, 30 Sept 2026): "Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026". Q32 Bio presented late-breaking results from Part B of the SIGNAL-AA Phase 2a trial of bempikibart in alopecia areata at the European Academy of Dermatology and Venereology Congress 2026, including data from the 36-week treatment period and a 16-week off-drug period. The company reported clinically meaningful efficacy on primary and key secondary endpoints, durable responses, biomarker and biopsy findings consistent with its mechanism of action, and a generally well-tolerated safety profile with no new safety signals.

Company

About Q32 Bio, Inc.

Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing biologic therapies for autoimmune and inflammatory diseases driven by immune system dysfunction. The company’s current programs center on restoring healthy immune balance through targeted modulation of the adaptive and innate immune systems, with a lead emphasis on treatments for alopecia areata and other immune-mediated conditions. Q32 Bio’s pipeline includes bempikibart, an antibody-based candidate designed to regulate immune signaling in dermatology and related autoimmune settings, as well as research efforts in complement-pathway biology for tissue-targeted immune control. The company’s work is positioned within the broader biopharmaceutical sector, where precision immunology and biologics play an important role in addressing chronic diseases with limited treatment options. Based in Waltham, Massachusetts, Q32 Bio continues to operate as a research-focused company advancing specialized therapies from clinical development programs.

CEO Ms. Jodie Pope Morrison · 22 employees · United States · https://www.q32bio.com